Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
HWRwxXeAPwQAKPZM
